Who
Ivan Cheung
Director
Company insider
Files Form 4 as: Director, Lexicon Pharmaceuticals.
In numbers
- Trades disclosed
- 11
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 2 Dec 2024
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,806 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —89,312 at $0.00 | filing |
| 2 Dec 2024filed 2 Dec 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,685 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.